Bioavailability evidence

Product

Measured material

Whole product

Endpoint

ADMET domain

Exposure / Absorption

Value

Observation

Telavancin has poor bioavailability and must be administered over 30-120 minutes IV.

Evidence role

Reported: reviewed reported observation that should not be pooled as a comparable value yet

Scientific context

Not specified

Condition

Route: IV · 85 · Telavancin · exact product name match · exact or normalized match

Scientific source

PepTherDia

Developability